Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed for myocardial perfusion imaging in patients undergoing stress and rest studies to assess coronary artery disease and myocardial viability.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and clinics worldwide.

Myoview (tetrofosmin) is used in cardiac imaging to evaluate myocardial perfusion.

- Myocardial perfusion imaging (stress and rest): Provides quantitative assessment of blood flow to detect ischemia. - Coronary artery disease detection: Helps identify obstructive lesions by comparing perfusion patterns. - Myocardial viability assessment: Differentiates viable from scarred myocardium to guide revascularization decisions.

Adverse reactions may occur following administration of Myoview.

Common Side Effects: - Nausea - Headache - Flushing - Injection site pain - Dizziness - Mild hypotension

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypotension - Life‑threatening arrhythmias - Acute respiratory distress - Significant chest pain - Persistent vomiting

Myoview requires careful consideration of patient condition and handling.

- Pregnancy: Safety not established; avoid unless essential. - Breastfeeding: Unknown risk; consider discontinuation. - Renal impairment: Monitor because clearance may be reduced. - Allergy: Assess for hypersensitivity to tetrofosmin or kit components. - Radiation exposure: Follow local regulations to limit dose to patient and staff. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before Myoview administration.

Major Interactions (Avoid): - Concurrent use of other radiopharmaceuticals emitting similar gamma energies may interfere with imaging. - Beta‑blockers may alter myocardial blood flow and affect image interpretation. - Vasodilators (e.g., nitrates) given shortly before may modify perfusion patterns.

Moderate Interactions (Monitor Closely): - Calcium channel blockers may modestly affect tracer uptake. - Thyroid disorders may influence radiotracer distribution.